Press Release Archive

 
01.26.2021 - Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • 84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
  • 82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year
  • Bone mineral density loss was minimal at Week 24 and remained stable through one year
  • Data to be included in New Drug Application submission to S.
 
01.26.2021 - Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • 84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
  • 82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year
  • Bone mineral density loss was minimal at Week 24 and remained stable through one year
  • Data to be included in New Drug Application submission to U.S.
 
01.25.2021 - European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
  • BAVENCIO maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study
  • First and only immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III trial
  • BAVENCIO first-line maintenance therapy is recommended for use by the ESMO Bladder Cancer Guidelines

Rockland, MA and New York, US, January 25, 2021 – EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in

 
01.22.2021 - Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
*/ /*-->*/ /*-->*/
  • Initial agreement provides up to 40 million doses to COVAX in 2021
  • First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure
  • For the COVAX Advanced Market Commit
 
01.20.2021 - Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTechSE (Nasdaq: BNTX) announced results f rom an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01.

 
01.14.2021 - Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults
*/ /*-->*/ /*-->*/

XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people

 
01.12.2021 - Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
*/ /*-->*/ /*-->*/

First four investments of new program created to support clinical-stage biotechnology companies

New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology

 
01.08.2021 - An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

New York, NY and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.

 
01.07.2021 - Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD).

 
01.05.2021 - Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39th Annual J.P. Morgan Healthcare Conference to be held virtually.

 
01.04.2021 - US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

- If approved, somatrogon will serve as a once-weekly treatment option –

NEW YORK & MIAMI--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Online Pfizer Press Kit